ANI Pharmaceuticals (ANIP) Getting Somewhat Positive Press Coverage, Study Finds
Media stories about ANI Pharmaceuticals (NASDAQ:ANIP) have trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. ANI Pharmaceuticals earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave press coverage about the specialty pharmaceutical company an impact score of 45.8993996766727 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
- Stock Price Activity Review for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) – Clawson News (clawsonnews.com)
- ANI Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ANIP-US : January 1, 2018 (finance.yahoo.com)
- ANI Pharmaceuticals acquires four AstraZeneca NDAs – Seeking Alpha (seekingalpha.com)
- ANI Pharmaceuticals (ANIP) Given a $77.00 Price Target by Canaccord Genuity Analysts (americanbankingnews.com)
- ANI Pharma (ANIP) Acquires US Rights to Four NDAs from AstraZeneca (AZN) for $46.5M – StreetInsider.com (streetinsider.com)
ANI Pharmaceuticals (NASDAQ ANIP) opened at $64.45 on Tuesday. The company has a market capitalization of $751.04, a price-to-earnings ratio of 100.70 and a beta of 2.90. The company has a debt-to-equity ratio of 0.83, a current ratio of 3.45 and a quick ratio of 2.39. ANI Pharmaceuticals has a 12 month low of $42.23 and a 12 month high of $74.70.
ANIP has been the topic of several research analyst reports. Canaccord Genuity set a $77.00 price target on shares of ANI Pharmaceuticals and gave the stock a “buy” rating in a report on Friday. ValuEngine raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, November 4th. TheStreet raised ANI Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Thursday, November 16th. BidaskClub cut ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, December 21st. Finally, Zacks Investment Research raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $71.00 target price on the stock in a research note on Tuesday, November 7th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $71.00.
TRADEMARK VIOLATION NOTICE: This piece was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://theolympiareport.com/2018/01/02/ani-pharmaceuticals-anip-getting-somewhat-positive-press-coverage-study-finds.html.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.